Beatrice A Chen1,2, Jingyang Zhang3, Holly M Gundacker3, Craig W Hendrix4, Craig J Hoesley5, Robert A Salata6, Charlene S Dezzutti1,2, Ariane van der Straten7, Wayne B Hall2, Cindy E Jacobson2, Sherri Johnson8, Ian McGowan2,9, Annalene M Nel10, Lydia Soto-Torres11, Mark A Marzinke4. 1. Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh. 2. Magee-Womens Research Institute, Pittsburgh, Pennsylvania. 3. Statistical Center for HIV/AIDS Research and Prevention/Fred Hutchinson Cancer Research Center, Seattle, Washington. 4. Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland. 5. Department of Medicine, University of Alabama at Birmingham. 6. Department of Medicine, Case Western Reserve University, Cleveland, Ohio. 7. Women's Global Health Imperative (WGHI) RTI International, San Francisco, California. 8. FHI 360, Durham, North Carolina. 9. Department of Medicine, University of Pittsburgh, Pennsylvania. 10. International Partnership for Microbicides, Silver Spring. 11. Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
Abstract
BACKGROUND:Postmenopausal women have unique sociobiological human immunodeficiency virus (HIV) risks. We evaluated the safety, pharmacokinetics, and acceptability of a microbicide dapivirine (DPV) vaginal ring (VR) versus placebo in postmenopausal women. METHODS: We enrolled 96 HIV-negative postmenopausal US women in a phase 2a double-blind, randomized (3:1) trial of monthly VRs containing 25 mg DPV or placebo used continuously for 12 weeks. We assessed safety by adverse events (AEs). DPV concentrations were quantified in plasma and vaginal fluid. Steady-state concentrations were analyzed at 4, 8, and 12 weeks using repeated measures ANOVA. We assessed acceptability by self-report. RESULTS: We found no differences in the proportion of women with related grade 2 or higher reproductive system AEs (DPV: 6/72 (8%), placebo: 3/24 (13%), P = .68) or grade 3 or higher AEs (DPV: 4/72 (6%), placebo: 0/24 (0%), P = .57). In the DPV arm, 2/72 (3%) declined to resume product use due to AEs. Median DPV concentrations in plasma (262.0 pg/mL at week 12) and vaginal fluid (40.6 ng/mg at week 12) were constant over 12 weeks and exceeded the in vitro 50% effective concentration by 5000-fold in vaginal fluid by week 4. VR acceptability was high; 84/93 (90%) "very much liked or liked" the VR. CONCLUSIONS: DPV VRs were safe, well tolerated, and acceptable in postmenopausal women. Plasma concentrations were comparable to published data on DPV use in reproductive-age women (median plasma concentration: 264 pg/mL). Given the reassuring safety and pharmacokinetic data, the DPV VR is promising for preexposure prophylaxis in postmenopausal women. CLINICAL TRIALS REGISTRATION: NCT02010593.
RCT Entities:
BACKGROUND: Postmenopausal women have unique sociobiological human immunodeficiency virus (HIV) risks. We evaluated the safety, pharmacokinetics, and acceptability of a microbicide dapivirine (DPV) vaginal ring (VR) versus placebo in postmenopausal women. METHODS: We enrolled 96 HIV-negative postmenopausal US women in a phase 2a double-blind, randomized (3:1) trial of monthly VRs containing 25 mg DPV or placebo used continuously for 12 weeks. We assessed safety by adverse events (AEs). DPV concentrations were quantified in plasma and vaginal fluid. Steady-state concentrations were analyzed at 4, 8, and 12 weeks using repeated measures ANOVA. We assessed acceptability by self-report. RESULTS: We found no differences in the proportion of women with related grade 2 or higher reproductive system AEs (DPV: 6/72 (8%), placebo: 3/24 (13%), P = .68) or grade 3 or higher AEs (DPV: 4/72 (6%), placebo: 0/24 (0%), P = .57). In the DPV arm, 2/72 (3%) declined to resume product use due to AEs. Median DPV concentrations in plasma (262.0 pg/mL at week 12) and vaginal fluid (40.6 ng/mg at week 12) were constant over 12 weeks and exceeded the in vitro 50% effective concentration by 5000-fold in vaginal fluid by week 4. VR acceptability was high; 84/93 (90%) "very much liked or liked" the VR. CONCLUSIONS:DPV VRs were safe, well tolerated, and acceptable in postmenopausal women. Plasma concentrations were comparable to published data on DPV use in reproductive-age women (median plasma concentration: 264 pg/mL). Given the reassuring safety and pharmacokinetic data, the DPV VR is promising for preexposure prophylaxis in postmenopausal women. CLINICAL TRIALS REGISTRATION: NCT02010593.
Authors: Jared M Baeten; Thesla Palanee-Phillips; Elizabeth R Brown; Katie Schwartz; Lydia E Soto-Torres; Vaneshree Govender; Nyaradzo M Mgodi; Flavia Matovu Kiweewa; Gonasagrie Nair; Felix Mhlanga; Samantha Siva; Linda-Gail Bekker; Nitesha Jeenarain; Zakir Gaffoor; Francis Martinson; Bonus Makanani; Arendevi Pather; Logashvari Naidoo; Marla Husnik; Barbra A Richardson; Urvi M Parikh; John W Mellors; Mark A Marzinke; Craig W Hendrix; Ariane van der Straten; Gita Ramjee; Zvavahera M Chirenje; Clemensia Nakabiito; Taha E Taha; Judith Jones; Ashley Mayo; Rachel Scheckter; Jennifer Berthiaume; Edward Livant; Cindy Jacobson; Patrick Ndase; Rhonda White; Karen Patterson; Donna Germuga; Beth Galaska; Katherine Bunge; Devika Singh; Daniel W Szydlo; Elizabeth T Montgomery; Barbara S Mensch; Kristine Torjesen; Cynthia I Grossman; Nahida Chakhtoura; Annalene Nel; Zeda Rosenberg; Ian McGowan; Sharon Hillier Journal: N Engl J Med Date: 2016-02-22 Impact factor: 91.245
Authors: Amie L Meditz; Kerrie L Moreau; Samantha MaWhinney; Wendolyn S Gozansky; Kelsey Melander; Wendy M Kohrt; Margaret E Wierman; Elizabeth Connick Journal: J Acquir Immune Defic Syndr Date: 2012-03-01 Impact factor: 3.731
Authors: Teresa L Parsons; Joshua F Emory; Lauren A Seserko; Wutyi S Aung; Mark A Marzinke Journal: J Pharm Biomed Anal Date: 2014-06-21 Impact factor: 3.935
Authors: Betsy C Herold; Beatrice A Chen; Robert A Salata; Mark A Marzinke; Clifton W Kelly; Charlene S Dezzutti; Ian McGowan; Beth Galaska; Lisa Levy; Jeanna M Piper; Sharon Hillier; Craig W Hendrix Journal: Clin Infect Dis Date: 2015-10-27 Impact factor: 9.079
Authors: José A Bauermeister; Jesse M Golinkoff; Alex Carballo-Diéguez; Rebecca Giguere; Daniela López; Craig J Hoesley; Beatrice A Chen; Peter Anderson; Charlene S Dezzutti; Julie Strizki; Carol Sprinkle; Faye Heard; Wayne Hall; Cindy Jacobson; Jennifer Berthiaume; Ashley Mayo; Barbra A Richardson; Jeanna Piper Journal: AIDS Behav Date: 2020-02
Authors: Michele N Austin; Leslie A Meyn; Hilary A Avolia; Melinda A Petrina; Lisa A Cosentino; Calins Alphonse; Beatrice A Chen; Katherine Bunge; Lisa Noguchi; Richard Beigi; Kathleen Squires; Sharon L Hillier Journal: J Infect Dis Date: 2022-06-15 Impact factor: 7.759
Authors: Kathleen Ridgeway; Elizabeth T Montgomery; Kevin Smith; Kristine Torjesen; Ariane van der Straten; Sharon L Achilles; Jennifer B Griffin Journal: Contraception Date: 2021-10-10 Impact factor: 3.051
Authors: Marie C D Stoner; Erica N Browne; Holly M Gundacker; Imogen Hawley; Beatrice A Chen; Craig Hoesley; Rachel Scheckter; Jeanna Piper; Devika Singh; Mei Song; Albert Liu; Ariane van der Straten Journal: PLoS One Date: 2022-02-22 Impact factor: 3.752
Authors: Mary Kate Shapley-Quinn; Nicole Laborde; Ellen Luecke; Craig Hoesley; Robert A Salata; Sherri Johnson; Annalene Nel; Lydia Soto-Torres; Beatrice A Chen; Ariane van der Straten Journal: AIDS Patient Care STDS Date: 2022-03 Impact factor: 5.944
Authors: Albert Y Liu; Clara Dominguez Islas; Holly Gundacker; Blazej Neradilek; Craig Hoesley; Ariane van der Straten; Craig W Hendrix; May Beamer; Cindy E Jacobson; Tara McClure; Tanya Harrell; Katherine Bunge; Brid Devlin; Jeremy Nuttall; Patrick Spence; John Steytler; Jeanna M Piper; Mark A Marzinke Journal: J Int AIDS Soc Date: 2021-06 Impact factor: 6.707